{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T21:30:12Z","timestamp":1786915812107,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Therapy with [<jats:sup>177<\/jats:sup>Lu]Lu-DOTATATE is well established for neuroendocrine tumors (NET), but its production generates [<jats:sup>177m<\/jats:sup>Lu], raising concerns about waste disposal due to its longer half-life. In contrast, [<jats:sup>177m<\/jats:sup>Lu] is not formed during [<jats:sup>177<\/jats:sup>Lu]Lu-DOTATOC production. However, data on overall survival (OS) and prognostic factors for [<jats:sup>177<\/jats:sup>Lu]Lu-DOTATOC remain limited, and its efficacy compared to [<jats:sup>177<\/jats:sup>Lu]Lu-DOTATATE is uncertain. This study aimed to analyze OS and radiological response in NET patients treated with [<jats:sup>177<\/jats:sup>Lu]Lu-DOTATOC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Monocentric, retrospective analysis of 141 patients with NET (grading: 21% G1, 71% G2, 4% G3, 4% grading unknown; primary: 48% small intestine (SI-NET); 27% pancreas (P-NET); 9% colon\/rectum; 1% stomach, 7% lung; 9% CUP-NET) receiving PRRT with [<jats:sup>177<\/jats:sup>Lu]Lu-DOTATOC. Cox and logistic regression were used to identify prognostic factors for OS or risk of primary progression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Death from any cause was observed in 85 of 141 patients (60.3%). Median OS was 55.2 months (SI NET G1-G2: 62.7 months; P-NET G1-G2: 41.2 months; NET G3: 26.3 months). Multivariable Cox regression identified baseline De Ritis Ratio (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), ALP (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), CgA (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and prior therapy with mTOR-inhibitors (<jats:italic>p<\/jats:italic>\u2009=\u20090.005) as significant prognostic factors of OS. Overall response rate was 12% and disease control rate was 72%. In multivariable logistic regression, primary tumor location (<jats:italic>p<\/jats:italic>\u2009=\u20090.04) and CgA (<jats:italic>p<\/jats:italic>\u2009=\u20090.01) were significant prognostic factors for higher risk of primary progression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The analysis of OS from routine clinical practice shows that PRRT with [<jats:sup>177<\/jats:sup>Lu]Lu-DOTATOC is an effective treatment option for NET patients, while generating minimal [<jats:sup>177m<\/jats:sup>Lu]. The evaluated prognostic factors could help to identify patients who particularly benefit from shorter follow-up intervals.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00259-025-07221-2","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T13:08:41Z","timestamp":1743340121000},"page":"3662-3671","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Beyond similarities: overall survival and prognostic insights from [\u00b9\u2077\u2077Lu]Lu-DOTATOC therapy in neuroendocrine tumors"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4693-5704","authenticated-orcid":false,"given":"Tristan","family":"Ruhwedel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Rogasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imke","family":"Schatka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Galler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Steinhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Amthauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"7221_CR1","doi-asserted-by":"publisher","unstructured":"Wu P, He D, Chang H, Zhang X. Epidemiologic trends of and factors associated with overall survival in patients with neuroendocrine tumors over the last two decades in the USA. Endocr Connect. 2023;12. https:\/\/doi.org\/10.1530\/EC-23-0331.","DOI":"10.1530\/EC-23-0331"},{"key":"7221_CR2","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, Oberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844\u201360. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.304.","journal-title":"Ann Oncol"},{"key":"7221_CR3","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. (177)Lu-Dotatate plus long-acting octreotide versus high\u2013dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752\u201363. https:\/\/doi.org\/10.1016\/S1470-2045(21)00572-6.","journal-title":"Lancet Oncol"},{"key":"7221_CR4","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2013dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403:2807\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(24)00701-3.","journal-title":"Lancet"},{"key":"7221_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/RLU.0000000000005479","volume":"50","author":"C Wetz","year":"2025","unstructured":"Wetz C, Ruhwedel T, Rogasch JMM, Steinhagen PR, Bolduan F, Amthauer H, et al. To perform, or not to perform interim PET: questioning the impact of midtherapy evaluation during PRRT in GEP-NET patients. Clin Nucl Med. 2025;50:19\u201324. https:\/\/doi.org\/10.1097\/RLU.0000000000005479.","journal-title":"Clin Nucl Med"},{"key":"7221_CR6","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1159\/000458155","volume":"105","author":"U Knigge","year":"2017","unstructured":"Knigge U, Capdevila J, Bartsch DK, Baudin E, Falkerby J, Kianmanesh R, et al. ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms: Follow-Up and Documentation. Neuroendocrinology. 2017;105:310\u20139. https:\/\/doi.org\/10.1159\/000458155.","journal-title":"Neuroendocrinology"},{"key":"7221_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","volume":"105","author":"RJ Hicks","year":"2017","unstructured":"Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology. 2017;105:295\u2013309. https:\/\/doi.org\/10.1159\/000475526.","journal-title":"Neuroendocrinology"},{"key":"7221_CR8","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1007\/s00259-020-04709-x","volume":"47","author":"J Strosberg","year":"2020","unstructured":"Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, et al. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with (177)Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020;47:2372\u201382. https:\/\/doi.org\/10.1007\/s00259-020-04709-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7221_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"Suppl 2","key":"7221_CR10","first-page":"S219","volume":"31","author":"EP Krenning","year":"1999","unstructured":"Krenning EP, Valkema R, Kooij PP, Breeman WA, Bakker WH, deHerder WW, et al. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide. Ital J Gastroenterol Hepatol. 1999;31(Suppl 2):S219\u201323.","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"7221_CR11","doi-asserted-by":"publisher","unstructured":"Ruhwedel T, Rogasch JMM, Huang K, Jann H, Schatka I, Furth C, et al. The prognostic value of the de Ritis ratio for Progression-Free survival in patients with NET undergoing [(177)Lu]Lu-DOTATOC-PRRT: A retrospective analysis. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13040635.","DOI":"10.3390\/cancers13040635"},{"key":"7221_CR12","doi-asserted-by":"publisher","unstructured":"Wetz C, Ruhwedel T, Schatka I, Grabowski J, Jann H, Metzger G, et al. Plasma markers for therapy response monitoring in patients with neuroendocrine tumors undergoing peptide receptor radionuclide therapy. Cancers (Basel). 2023;15. https:\/\/doi.org\/10.3390\/cancers15245717.","DOI":"10.3390\/cancers15245717"},{"key":"7221_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/0009-8981(57)90027-x","volume":"2","author":"F De Ritis","year":"1957","unstructured":"De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities. Clin Chim Acta. 1957;2:70\u20134. https:\/\/doi.org\/10.1016\/0009-8981(57)90027-x.","journal-title":"Clin Chim Acta"},{"key":"7221_CR14","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s10637-016-0363-6","volume":"34","author":"N Benslama","year":"2016","unstructured":"Benslama N, Bollard J, Vercherat C, Massoma P, Roche C, Hervieu V, et al. Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors. Invest New Drugs. 2016;34:654\u201362. https:\/\/doi.org\/10.1007\/s10637-016-0363-6.","journal-title":"Invest New Drugs"},{"key":"7221_CR15","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1210\/jc.2011-0666","volume":"96","author":"JC Yao","year":"2011","unstructured":"Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011;96:3741\u20139. https:\/\/doi.org\/10.1210\/jc.2011-0666.","journal-title":"J Clin Endocrinol Metab"},{"key":"7221_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"key":"7221_CR17","doi-asserted-by":"publisher","first-page":"756","DOI":"10.2967\/jnumed.116.185587","volume":"58","author":"M Barrio","year":"2017","unstructured":"Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, Du L, et al. The impact of somatostatin Receptor-Directed PET\/CT on the management of patients with neuroendocrine tumor: A systematic review and Meta-Analysis. J Nucl Med. 2017;58:756\u201361. https:\/\/doi.org\/10.2967\/jnumed.116.185587.","journal-title":"J Nucl Med"},{"key":"7221_CR18","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s00259-015-3041-6","volume":"42","author":"A Sabet","year":"2015","unstructured":"Sabet A, Dautzenberg K, Haslerud T, Aouf A, Sabet A, Simon B, et al. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Eur J Nucl Med Mol Imaging. 2015;42:1238\u201346. https:\/\/doi.org\/10.1007\/s00259-015-3041-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7221_CR19","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-Term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23:4617\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2743.","journal-title":"Clin Cancer Res"},{"key":"7221_CR20","doi-asserted-by":"publisher","unstructured":"Luna-Gutierrez M, Hernandez-Ramirez R, Soto-Abundiz A, Garcia-Perez O, Ancira-Cortez A, Lopez-Buenrostro S, et al. Improving overall survival and quality of life in patients with prostate cancer and neuroendocrine tumors using (177)Lu-iPSMA and (177)Lu-DOTATOC: experience after 905 treatment doses. Pharmaceutics. 2023;15. https:\/\/doi.org\/10.3390\/pharmaceutics15071988.","DOI":"10.3390\/pharmaceutics15071988"},{"key":"7221_CR21","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s00259-015-3030-9","volume":"42","author":"P Radojewski","year":"2015","unstructured":"Radojewski P, Dumont R, Marincek N, Brunner P, Macke HR, Muller-Brand J, et al. Towards tailored radiopeptide therapy. Eur J Nucl Med Mol Imaging. 2015;42:1231\u20137. https:\/\/doi.org\/10.1007\/s00259-015-3030-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7221_CR22","doi-asserted-by":"publisher","first-page":"e19304","DOI":"10.1097\/MD.0000000000019304","volume":"99","author":"LF Wang","year":"2020","unstructured":"Wang LF, Lin L, Wang MJ, Li Y. The therapeutic efficacy of 177Lu-DOTATATE\/DOTATOC in advanced neuroendocrine tumors: A meta-analysis. Med (Baltim). 2020;99:e19304. https:\/\/doi.org\/10.1097\/MD.0000000000019304.","journal-title":"Med (Baltim)"},{"key":"7221_CR23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.7150\/thno.13702","volume":"6","author":"RP Baum","year":"2016","unstructured":"Baum RP, Kluge AW, Kulkarni H, Schorr-Neufing U, Niepsch K, Bitterlich N, et al. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) for peptide receptor radiotherapy in patients with advanced neuroendocrine tumours: A Phase-II study. Theranostics. 2016;6:501\u201310. https:\/\/doi.org\/10.7150\/thno.13702.","journal-title":"Theranostics"},{"key":"7221_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s002590050034","volume":"27","author":"JC Reubi","year":"2000","unstructured":"Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273\u201382. https:\/\/doi.org\/10.1007\/s002590050034.","journal-title":"Eur J Nucl Med"},{"key":"7221_CR25","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1007\/s00259-006-0172-9","volume":"33","author":"JP Esser","year":"2006","unstructured":"Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, Bakker WH, et al. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging. 2006;33:1346\u201351. https:\/\/doi.org\/10.1007\/s00259-006-0172-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7221_CR26","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","volume":"52","author":"TD Poeppel","year":"2011","unstructured":"Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52:1864\u201370. https:\/\/doi.org\/10.2967\/jnumed.111.091165.","journal-title":"J Nucl Med"},{"key":"7221_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/978-3-642-27994-2_30","volume":"194","author":"C Schuchardt","year":"2013","unstructured":"Schuchardt C, Kulkarni HR, Prasad V, Zachert C, Muller D, Baum RP. The bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC. Recent Results Cancer Res. 2013;194:519\u201336. https:\/\/doi.org\/10.1007\/978-3-642-27994-2_30.","journal-title":"Recent Results Cancer Res"},{"key":"7221_CR28","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.7150\/thno.98053","volume":"14","author":"A Akhavanallaf","year":"2024","unstructured":"Akhavanallaf A, Joshi S, Mohan A, Worden FP, Krauss JC, Zaidi H, et al. Enhancing precision: A predictive model for (177)Lu-DOTATATE treatment response in neuroendocrine tumors using quantitative (68)Ga-DOTATATE PET and clinicopathological biomarkers. Theranostics. 2024;14:3708\u201318. https:\/\/doi.org\/10.7150\/thno.98053.","journal-title":"Theranostics"},{"key":"7221_CR29","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1159\/000506746","volume":"111","author":"K Fross-Baron","year":"2021","unstructured":"Fross-Baron K, Garske-Roman U, Welin S, Granberg D, Eriksson B, Khan T, et al. 177Lu-DOTATATE therapy of advanced pancreatic neuroendocrine tumors heavily pretreated with chemotherapy: analysis of outcome, safety, and their determinants. Neuroendocrinology. 2021;111:330\u201343. https:\/\/doi.org\/10.1159\/000506746.","journal-title":"Neuroendocrinology"},{"key":"7221_CR30","doi-asserted-by":"publisher","unstructured":"Galler M, Rogasch JMM, Huang K, Jann H, Plehm K, Wetz C, et al. Prognostic value of the largest lesion size for Progression-Free survival in patients with NET undergoing salvage PRRT with [(177)Lu]Lu-DOTATOC. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14071768.","DOI":"10.3390\/cancers14071768"},{"key":"7221_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1530\/ERC-21-0248","volume":"29","author":"L Chen","year":"2022","unstructured":"Chen L, Gnanasegaran G, Mandair D, Toumpanakis C, Caplin M, Navalkissoor S. Prognostic stratification for patients with neuroendocrine tumours receiving 177Lu-Dotatate. Endocr Relat Cancer. 2022;29:111\u201320. https:\/\/doi.org\/10.1530\/ERC-21-0248.","journal-title":"Endocr Relat Cancer"},{"key":"7221_CR32","doi-asserted-by":"publisher","first-page":"1169970","DOI":"10.3389\/fmed.2023.1169970","volume":"10","author":"NF Trautwein","year":"2023","unstructured":"Trautwein NF, Schwenck J, Jacoby J, Reischl G, Fiz F, Zender L, et al. Long-term prognostic factors for PRRT in neuroendocrine tumors. Front Med (Lausanne). 2023;10:1169970. https:\/\/doi.org\/10.3389\/fmed.2023.1169970.","journal-title":"Front Med (Lausanne)"},{"key":"7221_CR33","doi-asserted-by":"publisher","unstructured":"Ladriere T, Faudemer J, Levigoureux E, Peyronnet D, Desmonts C, Vigne J. Safety and therapeutic optimization of Lutetium-177 based radiopharmaceuticals. Pharmaceutics. 2023;15. https:\/\/doi.org\/10.3390\/pharmaceutics15041240.","DOI":"10.3390\/pharmaceutics15041240"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07221-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07221-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07221-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T01:05:31Z","timestamp":1754355931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07221-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["7221"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07221-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This analysis was conducted in accordance with the guidelines of the Declaration of Helsinki and approved by the Institutional Ethics Committee of Charit\u00e9\u2013 Universit\u00e4tsmedizin Berlin (reference ID: EA2\/006\/20).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}